Merck Stock Dips 237% in Two Days Despite $981 Billion Trading Volume Ranking 72nd

On May 2, 2025, Merck & Co., Inc. (MRK) experienced a slight decline of 0.10%, marking its second consecutive day of decrease, with a total drop of 2.37% over the past two days. The trading volume for the day was $9.81 billion, placing it at the 72nd position in the overall market rankings.

Merck has initiated construction on a $1 billion biologics center in Delaware, which is set to become a key production hub for Keytruda in the United States. This strategic investment aims to bolster Merck's domestic manufacturing capabilities and ensure a steady supply of biologic drugs amidst potential tariff threats.

In addition to the new facility, Merck has reported significant advancements in its clinical trials. The company's KEYTRUDA® (pembrolizumab) has shown promising results as a perioperative treatment when combined with standard of care adjuvant therapy. This combination significantly improved event-free survival in patients with resectable locally advanced head and neck squamous cell carcinoma compared to standard of care alone.

Merck's commitment to innovation and long-term value creation for its stakeholders is evident in its recent financial performance. The company's Q4 and full-year 2024 results reflect strong growth, with worldwide sales reaching $15.6 billion in Q4 2024, a 7% increase from the previous year. Full-year 2024 sales amounted to $64.2 billion, also a 7% increase from 2023.